Press Release

CStone Enters Exclusive Collaboration With Blueprint Medicines

June 26, 2018

Shanghai – June 26, 2018 – Cooley advised CStone Pharmaceuticals on its exclusive collaboration and license agreement with Blueprint Medicines to develop and commercialize its cancer therapy, avapritnib, in mainland China, Hong Kong, Macau and Taiwan. Partner Christina Zhang led the Cooley team advising CStone.

Under the terms of the agreement, CStone will make an upfront payment of $40 million in cash to Blueprint. Blueprint is also eligible to receive approximately $346 million in potential milestone payments in addition to tiered percentage royalties.  

"Based on the compelling clinical data reported to date, we believe Blueprint Medicines' targeted therapies – avapritinib, BLU-554 and BLU-667 – hold promise for dramatically altering the treatment landscape for patients in China with gastrointestinal stromal tumors, hepatocellular carcinoma, non-small cell lung cancer and other cancers,” said Frank Jiang, CStone’s chief executive officer, in a news release. 

CStone is a Shanghai and Suzhou-based innovative biopharmaceutical company devoted to the development of a new generation of innovative drugs.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.